Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of CDP-Choline (Citicoline) and CMS121 — mechanism, dosing, side effects, legal status, and pricing.
CDP-choline (citicoline) is a non-peptide cytidine nucleotide-choline conjugate that serves as an intermediate in phosphatidylcholine biosynthesis. It is approved as a prescription drug for stroke and cognitive disorders in Japan and parts of Europe but sold only as a dietary supplement ingredient in the United States, where it is not FDA-approved as a drug. Human evidence is mixed and indication-dependent: small trials report modest memory improvements in healthy/older adults, but the largest phase 3 RCT (COBRIT, n=1,213 traumatic brain injury patients) found no benefit over placebo.
CMS121 is a non-peptide small-molecule quinoline, a synthetic analog of the natural flavonoid fisetin, developed to inhibit fatty acid synthase (FASN) and reduce lipid peroxidation in neuronal cells. It has completed a Phase 1 safety and pharmacokinetics trial in healthy volunteers (NCT05318040) but has no approved medical use and no published human efficacy data in Alzheimer's disease or any other condition. The compound is sold by research-chemical suppliers for laboratory use only; some direct-to-consumer vendors incorrectly market it as a "peptide" supplement despite its small-molecule structure.
CDP-Choline (Citicoline)
CMS121
Category
Legal Status
Mechanism
Dose Range
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
CDP-Choline (Citicoline)
No pricing data yet.
Check CDP-Choline (Citicoline) prices →CMS121
COA corpus from Disclosed Labs — independently tested batches only.
CDP-Choline (Citicoline)
No COA data yet.
Submit testing data →CMS121
3
COAs
99.1%
Avg purity
2
Labs
Human evidence is mixed and indication-dependent. Small-to-moderate placebo-controlled RCTs in healthy/older adults and age-associated memory impairment report modest verbal/episodic memory improvements at ~500–1,000 mg/day over weeks to months. However, the largest trial to date—COBRIT, a phase 3 double-blind placebo-controlled RCT in 1,213 traumatic brain injury patients—found no benefit over placebo on functional or cognitive outcomes (GOS-E favorable outcome 35.4% citicoline vs 35.6% placebo; global OR 0.98, 95% CI 0.83–1.15). Evidence for Alzheimer's disease and MCI is described in reviews as insufficient and inconsistent. In preclinical models, aged rats with hippocampal damage showed reduced long-term memory impairment with dietary CDP-choline supplementation, and mice subjected to ischemic stroke showed SIRT1-dependent reduction in cerebral infarct volume.
Key references
In APPswe/PS1dE9 double-transgenic mice (a model of Alzheimer's disease), dietary CMS121 (~34 mg/kg/day for 3 months starting at 9 months of age) normalized elevated hippocampal 4-HNE lipid-peroxidation adducts to wild-type levels, reduced 15-LOX2 and GFAP expression, and reversed cognitive deficits in Morris water maze testing to performance indistinguishable from wild-type mice. In vitro, CMS121 reduced iNOS, COX2, and TNF-α induction and blunted lipid-peroxidation increases in LPS-activated microglial cell cultures. A completed Phase 1 trial in approximately 100 healthy volunteers (NCT05318040) tested single oral doses up to 1800 mg and repeat doses up to 900 mg/day in young adults (600 mg/day in elderly subjects) for 7 days, reporting generally well-tolerated safety profiles with the majority of adverse events classified as mild; no serious adverse events were reported. Elderly subjects showed higher systemic exposure and longer terminal half-life than young adults, and fed-state exposure was approximately 50% higher than fasted with delayed absorption. No human efficacy data exist in Alzheimer's disease patients or any patient population.
CDP-Choline (Citicoline) and CMS121 are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs